Back to results
US 10,350,275 B2Granted
Methods of cytotoxic gene therapy to treat tumors
AssigneeAdvantagene, Inc.
InventorCarlos Estuardo Aguilar-Cordova
Life of this patent
Estimating the term…
Abstract
A method is disclosed for decreasing or retarding an increase in the size of a localized or metastatic tumor by using a combination of an immune stimulating cytotoxic gene therapy and immune-checkpoint modulating agent, in conjunction with other therapies, including radiation therapy, chemotherapy, surgery, and immunotherapies.
Claims6
A method of decreasing tumor burden in a mammal comprising:
- i) administering a replication-incompetent adenoviral vector encoding thymidine kinase to a mammal with a tumor intratumorally;
- ii) administering a prodrug to the mammal orally or intravenously, wherein the prodrug is ganciclovir, acyclovir, valacyclovir, valgancyclovir, famiciclovir, or an active analog thereof, such that the prodrug is activated by the thymidine kinase;
- and
- iii) administering a monoclonal antibody that recognizes the checkpoint protein PD1 to the mammal intravenously such that the antibody reduces the immune repressive response caused by the checkpoint protein, thereby allowing enhanced T cell activation,
- wherein the activated prodrug and enhanced T cell activation decrease tumor burden.
2 more elements
A method of treating a mammal with a tumor resection comprising:
- i) administering a replication-incompetent adenoviral vector encoding thymidine kinase to a tumor resection site in a mammal;
- ii) administering a prodrug to the mammal orally or intravenously, wherein the prodrug is ganciclovir, acyclovir, valacyclovir, valgancyclovir, famiciclovir, or an active analog thereof, such that the prodrug is activated by the thymidine kinase;
- and
- iii) administering a monoclonal antibody that recognizes the checkpoint protein PD1 to the mammal intravenously such that the antibody reduces the immune repressive response caused by the checkpoint protein, thereby allowing enhanced T cell activation,
- wherein the activated prodrug and enhanced T cell activation decrease micrometastases.
2 more elements
Dependencies are inferred from the claim text.